Stephens Inc. AR Grows Stock Holdings in Insulet Co. (NASDAQ:PODD)

Stephens Inc. AR grew its holdings in Insulet Co. (NASDAQ:PODDGet Rating) by 57.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,335 shares of the medical instruments supplier’s stock after purchasing an additional 855 shares during the quarter. Stephens Inc. AR’s holdings in Insulet were worth $622,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of PODD. Capital Research Global Investors lifted its stake in Insulet by 8.0% in the 4th quarter. Capital Research Global Investors now owns 7,811,512 shares of the medical instruments supplier’s stock worth $2,078,434,000 after purchasing an additional 579,764 shares in the last quarter. Marshall Wace LLP purchased a new position in Insulet in the 4th quarter worth approximately $140,781,000. D1 Capital Partners L.P. lifted its stake in Insulet by 27.9% in the 4th quarter. D1 Capital Partners L.P. now owns 1,692,857 shares of the medical instruments supplier’s stock worth $450,418,000 after purchasing an additional 368,775 shares in the last quarter. Ownership Capital B.V. purchased a new position in Insulet in the 1st quarter worth approximately $45,014,000. Finally, Blair William & Co. IL lifted its stake in Insulet by 1,412.4% in the 4th quarter. Blair William & Co. IL now owns 173,639 shares of the medical instruments supplier’s stock worth $46,200,000 after purchasing an additional 162,158 shares in the last quarter.

Insiders Place Their Bets

In other Insulet news, Director Shacey Petrovic sold 15,000 shares of the business’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $222.90, for a total value of $3,343,500.00. Following the completion of the transaction, the director now owns 13,695 shares in the company, valued at $3,052,615.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, COO Charles Alpuche sold 6,000 shares of Insulet stock in a transaction on Monday, June 6th. The shares were sold at an average price of $215.32, for a total transaction of $1,291,920.00. Following the completion of the sale, the chief operating officer now directly owns 43,899 shares of the company’s stock, valued at approximately $9,452,332.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction on Friday, July 1st. The stock was sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the sale, the director now directly owns 13,695 shares of the company’s stock, valued at $3,052,615.50. The disclosure for this sale can be found here. Insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

PODD has been the subject of a number of recent analyst reports. Wells Fargo & Company cut their price target on shares of Insulet from $357.00 to $345.00 in a report on Friday, May 6th. Citigroup downgraded shares of Insulet from a “buy” rating to a “neutral” rating and cut their price target for the stock from $310.00 to $250.00 in a report on Monday, July 11th. BTIG Research cut their price target on shares of Insulet from $310.00 to $250.00 and set a “buy” rating for the company in a report on Friday, June 24th. Finally, Morgan Stanley cut their price target on shares of Insulet from $268.00 to $244.00 and set an “equal weight” rating for the company in a report on Tuesday, June 7th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $286.73.

Insulet Stock Performance

NASDAQ:PODD opened at $257.06 on Wednesday. The company has a fifty day simple moving average of $224.31 and a two-hundred day simple moving average of $235.12. The company has a market cap of $17.82 billion, a price-to-earnings ratio of 408.04 and a beta of 0.73. The company has a quick ratio of 4.51, a current ratio of 5.98 and a debt-to-equity ratio of 3.11. Insulet Co. has a 52 week low of $181.00 and a 52 week high of $324.81.

Insulet (NASDAQ:PODDGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $0.40 EPS for the quarter, topping the consensus estimate of $0.23 by $0.17. The business had revenue of $295.40 million during the quarter, compared to the consensus estimate of $287.99 million. Insulet had a net margin of 3.91% and a return on equity of 15.81%. The business’s revenue for the quarter was up 17.1% on a year-over-year basis. As a group, equities analysts anticipate that Insulet Co. will post 1.3 earnings per share for the current fiscal year.

Insulet Company Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Further Reading

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDGet Rating).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.